Pregabalin (All indications) updated on 04-22-2025

Urinary malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19303
R81718		 Beau (Indications NOS), 2026 Urinary anomalies 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 0.81 [0.26;2.57] 3/20   22,290/146,202 22,293 20
ref
S15251
R62704		 Dudukina (Controls exposed to LTG) (Mixed indications), 2023 Urinary malformations 3 months or more before pregnancy or1st trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes 2.49 [1.04;5.96]
excluded (control group) 		-/2,332   -/7,005 - 2,332
ref
S15252
R62725		 Dudukina (Controls unexposed, NOS) (Mixed indications), 2023 Urinary malformations 3 months or more before pregnancy or1st trimester excluded population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.15 [0.62;2.14]
excluded (exposition period) 		-/2,332   -/3,063,173 - 2,332
ref
Total 1 studies 0.81 [0.26;2.55] 22,293 20
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Beau (Indications NOS), 2026Beau, 2026 1 0.81[0.26; 2.57]22,293200%ROB confusion: criticalROB selection: criticalROB classification: unclearROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0.81[0.26; 2.55]22,29320 -NABeau (Indications NOS), 2026 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.81[0.26; 2.55]22,29320 -NABeau (Indications NOS), 2026 1 Tags Adjustment   - Yes  - Yes 0.81[0.26; 2.55]22,29320 -NABeau (Indications NOS), 2026 1 All studiesAll studies 0.81[0.26; 2.55]22,29320 -NABeau (Indications NOS), 2026 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 15251

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.81[0.26; 2.55]22,29320 -NABeau (Indications NOS), 2026 1 design cohort studycohort study 0 case controlcase control 0.81[0.26; 2.55]22,29320 -NABeau (Indications NOS), 2026 1 case-time-controlcase-time-control 0 case-case-time-controlcase-case-time-control 0 otherother 00.510.01.0